The FDA has cleared the initiation of a pivotal Phase 3 trial testing pridopidine in people with early, rapidly progressive ...

Qalsody is one step closer to being covered by public Canadian healthcare systems when used to treat adults with ALS with ...

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

The study will be carried out at up to 60 ALS treatment centres across Canada, the EU, the US, Israel and the UK.

In March 2024, Kayla Gonzalez started having an odd sensation behind her right kneecap. At first, she didn’t think much of it. Then, the feeling started to spread. Soon, she had weakness in her calf, ...

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) ...

This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...

This funding was awarded through the ALS Association's Hoffman ALS Clinical Trial Awards Program, which aims to accelerate the development of new ALS treatments ARLINGTON, Va., Dec. 4, 2025 ...

PathMaker Neurosystems Inc. ('PathMaker”), a clinical-stage neurotechnology company developing a breakthrough non-invasive approach for treating Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...